Genotypic diversity, prevalence and epidemiological assessment of various variants of human papillomavirus coinfection in patients with dermatovenereological profile

vaccination and screening are the most effective methods for reducing cervical cancer incidence and mortality. With high immunization coverage, there is a potential for changes in the pattern of HPV types circulating in the population, increasing the risk of reduced effectiveness of vaccination programs. Studying genotypic diversity, the prevalence of coinfections, and the interactions of HPV genotypes in different populations is a complex task for determining the oncogenic potential of the pathogen and assessing the effectiveness of vaccination. Study objective. To study the genotypic diversity and prevalence of highly oncogenic HPV types and to conduct an epidemiological assessment of coinfection patterns in patients at risk for sexually transmitted infections (STIs). Materials and methods. From 2005 to 2024, 9,056 patients were examined, including 1,269 women without complaints or clinical manifestations of disease and 751 patients with STIs. They were tested for STIs and identified 12 HPV genotypes. Research methods included PCR, clinical, epidemiological, and statistical methods. Results and discussion. The prevalence of HPV among patients with dermatovenereological profile was 28.4 %. The most common HPV types in patients at risk for STIs are both vaccine-relevant (HPV 16) and non-vaccine-relevant (HPV 31, 33, 35, 45, 56, 58) genotypes of the virus, which is important to consider when developing screening and prevention programs. The prevalence of HPV and STI coinfections was revealed in 74.7 % of cases, including 74.9 % in mycoureaplasmosis. Multiple HPV infection was detected in 15 % of cases, while the most frequent combinations of HPV VCR included genotypes 16, 31, 33, 35 and 56. Based on statistical analysis, competitive interactions are suggested between certain pairs of HPV genotypes.